Neurotrope Submits an Amended Protocol to the U.S. Food and Drug Administration for its Phase 2b Clinical Trial of its Lead Drug Candidate, Bryostatin-1, for the Treatment of Advanced …

is lower in apoE4 transgenic mice compared with apoE3 mice, indicating impaired synaptogen-esis (12, 13). ApoE4 is less efficient than apoE3 in transporting brain cholesterol (14) and is …

Plantation, FL. – June 19, 2014 – Neurotrope, Inc. (OTCQB: NTRP) has appointed Messrs. Charles S. Ramat and Paul Freiman as Co-Chairmen of its Board of Directors. Mr. Freiman …

The complete publication in the Trends in Pharmacological Sciences: CellPress Reviews can be accessed here: https://www.synaptogen.com/wp-content/uploads/2019//08/TiPS2019.pdf and …

Bryostatin, currently being tested in a Phase 2b clinical trial in Alzheimer’s Dementia, causes regeneration of synaptic networks in both Alzheimer’s and Fragile X mouse models, …

Synaptogenix | Press Release 261 archive,category,category-press-release,category-261,ajax_fade,page_not_loaded,,select-theme-ver-4.4,smooth_scroll,wpb-js-composer js …

Dec 5, 2014 · Apolipoprotein E (ApoE) is a critical signal for synaptogen-esis and synaptic maturation [101]. ApoE/cholesterol com-plex released from astrocytes is taken up through low …

Morgantown, WV 26505 Running title: Rescuing synapses and spatial memory in young fragile X mice

Plantation, FL. – October 7, 2013 – Neurotrope, Inc. (formerly BlueFlash Communications, Inc.) (OTCQB:NTRP), a Nevada corporation (the “Company”), announced today that it has formally …

NEW YORK, March 24, 2017 /PRNewswire/ — Neurotrope, Inc. (OTCQB: NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, …